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Abstract
Background To test the hypothesis that neurofilament light (NfL) in CSF is a biomarker of CNS involvement in patients with 
systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS), we measured NfL in CSF from 52 patients with 
lupus and 54 with pSS and explored associations with clinical, structural, immunological and biochemical abnormalities.
Methods In CSF, we measured NfL, anti-P antibodies, protein S100B and TWEAK by ELISA and anti-NR2 antibodies by 
electrochemiluminescence. Anti-phospholipid antibodies and routine immunological tests were performed in blood. IgG and 
albumin were measured in CSF and serum for assessment of the blood–brain barrier function (Q-albumin) and intrathecal 
IgG production (IgG index). Cerebral MRI and neuropsychological testing were performed.
Results A multivariable regression model showed that increasing CSF anti-NR2 antibody levels were associated with increas-
ing NfL levels in patients with SLE (B 1.27, 95% CI 0.88–1.65, p < 0.001). Age contributed significantly in the model (B 
0.04, 95% CI 0.03–0.05, p < 0.001). Similar findings were observed in the pSS group. Adjusted for age and sex, no associa-
tions were found between NfL levels and any MRI data. In SLE patients, higher NfL concentrations were associated with 
impairments in psychomotor speed and motor function, and in pSS with motor dysfunction. These associations remained 
in multivariable regression models.
Conclusions Increased concentration of NfL in CSF is a marker of cerebral involvement in patients with SLE and pSS, is 
strongly associated with the presence of anti-NR2 antibodies, and correlates with cognitive impairment in several domains.
Keywords Neurofilament light chain · Anti-NR2 antibodies · Cognitive dysfunction · Systemic lupus erythematosus · 
Primary Sjögrens´s syndrome
Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic 
inflammatory autoimmune disease that frequently involves 
the CNS [1]. The manifestations are diverse, varying from 
life-threatening strokes and encephalitis to headaches and 
mood disorders. Primary Sjögren’s syndrome (pSS) is 
another systemic inflammatory autoimmune disease that 
primarily attacks exocrine glands, such as the salivary and 
lacrimal glands, leading to dryness of the mouth and eyes 
[2]. Neuropsychiatric phenomena are common in both dis-
eases [3].
Neurofilament light chain protein (NfL) is one out of five 
neurofilament subunits that comprise the neuronal cytoskel-
eton. Increased NfL levels in CSF reflect axonal damage 
and degeneration; consequently, NfL is frequently used as a 
marker of CNS injury in neurodegenerative conditions, mul-
tiple sclerosis, cerebrovascular diseases, and traumatic brain 
injury (Fig. 1) [4]. We hypothesized that NfL levels in CSF 
would be increased in patients with SLE and/or pSS. We also 
hypothesized that increased NfL levels might be associated 
with brain reactive antibodies, such as anti-phospholipid 
antibodies (aPL antibodies) [5, 6], antibodies against the 
NR2 subunit of the N-methyl-d-aspartate receptor (anti-NR2 
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antibodies) [7, 8], or antibodies directed against ribosomal 
P proteins (anti-P antibodies) [9].
The present study aimed to determine whether CSF NfL 
could serve as a biomarker of CNS involvement in SLE and/
or pSS. To that end, we investigated potential associations 
between NfL concentrations and structural, immunologi-
cal, and biochemical abnormalities in patients with SLE 
and pSS. In addition, we investigated whether functional 
abnormalities were evident in patients with increased NfL 
levels, exemplified by cognitive dysfunction or headache.
Methods
Nearly, all patients with systemic autoimmune diseases in 
Rogaland County, Norway, are allocated to Stavanger Uni-
versity Hospital, where this study was performed. Recruit-
ment was based on hospital records from in- and outpatients.
SLE group
Eighty-six patients, all Caucasian, fulfilled the 1982 revised 
American College of Rheumatology (ACR) criteria for 
SLE [10]. Of these, 70 (81%) consented to participate in 
the study. Two patients withdrew consent, and one was 
excluded, due to a brain tumor. Thus, 67 patients (78%) were 
included in the study.
PSS group
Seventy-two (73%) out of 99 patients, all Caucasian, fulfilled 
the American European Consensus Group (AECG) criteria 
for pSS [11], and consented to participate in the study. One 
patient was excluded due to a brain tumor. Thus, 71 (72%) 
patients were included.
Clinical examination
All patients were examined by two internists (EH and LG) 
and a neurologist (ABT) during a 2-day stay in the hospi-
tal, for research purposes only. SLE disease activity was 
assessed with the SLE disease activity index (SLEDAI) [12], 
and organ damage was assessed with The Systemic Lupus 
International Collaborating Clinics/American College of 
Rheumatology Damage Index (SLICC/ACR-DI) [13]. Head-
ache was assessed in a structured interview, and classified 
according to the International Classification of Headache 
Disorders (ICHD II) [14]. Depression was assessed with the 
Beck Depression Inventory (BDI) applying a cut-off score 
of ≥ 13 to identify current clinical depression [15]. Fatigue 
severity was scored by the fatigue Visual Analogue Scale 
(fVAS) [16]. Arterial hypertension was defined as systolic 
blood pressure ≥ 140 and/or diastolic pressure ≥ 90 mmHg 
or current use of antihypertensive medication.
Lumbar puncture
Fifty-two of the 67 patients with SLE (78%) and 54 of the 71 
patients with pSS (76%) underwent lumbar punctures. All 
CSF samples were obtained between 1 and 2 p.m., placed 
on ice, and centrifuged at 4 °C at 3000×g for 10 min. Super-




IgG was measured in CSF and serum with the Cobas Inte-
gra Immunoglobulin G (Turbidimetric) assay, and albumin 
with Tina-quant a Albumin Gen.2 (Roche Diagnostics, Man-
nheim, Germany) according to the manufacturer`s instruc-
tions. The CSF/serum albumin ratio (Q-albumin) was cal-
culated as [CSF-albumin/serum-albumin] as a measure 
of the blood–brain barrier function, while the IgG index 
was calculated as [(CSF-IgG/serum-IgG)/(CSF-albumin/
serum-albumin)] as a measure for intrathecal IgG produc-
tion, and chronic CNS inflammation [17]. Anti-NR2 anti-
bodies were detected by electrochemiluminescence [8] 
and anti-P antibodies by ELISA [18], both as previously 
described. Protein S100B was analyzed with the Human 
S100B ELISA kit (Abnova, Jhongli City, Taiwan) accord-
ing to the manufacturer`s instructions, and TNF-like weak 
inducer of apoptosis (TWEAK) by ELISA (R&D Systems, 
Minneapolis, MN, USA) as previously described [19]. CSF 
NfL concentration was measured using a commercially 
Fig. 1  Neuron with neurofilaments. Figure illustrates disintegrating 
neurofilaments, and neurofilament light chains (NfL) leaking out of 
the axon. Figure created with BioRender.com
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available ELISA according to instructions from the manu-
facturer (UmanDiagnostics, Umeå, Sweden). The meas-
urements were performed in one round of experiments by 
board-certified laboratory technicians who were blinded to 
the clinical data. Intra-assay coefficients of variation were 
below 10%.
Blood
Routine biochemical, hematological, and immunologi-
cal analyses were performed at the hospital’s laboratories. 
ANA was detected with the HEp-2000 assay (Immunocon-
cepts, Sacramento, CA, USA), and presence of anti-double-
stranded (ds) DNA by Nova Lite dsDNA Crithidia luciliae 
708,200 indirect immunofluorescence assay (Nova Diagnos-
tics, San Diego, CA, USA). Anti-SSA, and anti-SSB anti-
bodies were measured by ELISA with QUANTA Lite ENA 
6 assay (Inova Diagnostics, San Diego, CA, USA), and posi-
tive results confirmed by Quanta Lite SSA and SSB ELISA 
(Inova Diagnostics). Anti-cardiolipin IgM and IgG antibod-
ies were measured with the QUANTA Lite™ ACA IgM and 
IgG ELISA (Inova Diagnostics). Lupus anticoagulant was 
measured by the activated partial thromboplastin time and 
dilute Russell’s viper venom time (Dade Behring, Marburg, 
Germany). Anti-phospholipid (aPL) antibodies were con-
sidered present if the patient had a positive anti-cardiolipin 
IgM- or IgG-antibody test, was lupus-anticoagulant positive, 
or any combinations of these.
MRI
MRI examinations were performed with a 1.5-T Philips 
Gyroscan NT Intera Release 10 (Philips Medical Systems, 
Best, The Netherlands). White matter hyperintensities 
(WMHs) were assessed in accordance with the semi-quanti-
tative visual rating scale of Scheltens et al. [20]. Global GM 
and WM volumes were estimated using the VBM8 extension 
of the SPM8 software. Details of the MRI protocols and 
preprocessing are previously described [21].
Neuropsychological testing
The tests were administered by a trained psychometric test 
technician. Results were analyzed by a clinical neuropsy-
chologist (SSM). The test batteries included the Wechsler 
Memory Scale, Revised (WMS-R) [22], Wechsler Adult 
Intelligence Scale (WAIS) [23], Stroop Color-Word Inter-
ference Test [24], Wisconsin Card Sorting Test [25], FAS 
Verbal Influency Test [26], Tactual Performance Test (TPT), 
Fingertapping test, Trail Making Test A and B, Category 
Test, Seashore Rhythm Test, Lafayette’s Hand Dynamometer 
Test, and the Lafayette Grooved Pegboard Test [27]. These 
tests mapped functions in eight cognitive domains: memory, 
psychomotor speed, visual–spatial processing, motor func-
tion, language, reasoning/problem solving, simple attention 
and complex attention. Scores were compared to normative 
data for each test, and cut-off score for abnormality defined 
by a standardized score ≥ 2SD from the reference mean. 
Cognitive dysfunction was defined as abnormality in one 
or more of these domains. The neuropsychological tests are 
based on normative data that are adjusted for age, sex and 
education.
Statistics
Continuous data are reported as medians and ranges. Cat-
egorical data are reported as numbers and percentages. Dif-
ferences between groups were evaluated with the chi-square 
test for categorical data, and the Mann–Whitney U test for 
continuous data. NfL measurements were log-transformed to 
achieve a less skewed distribution, more appropriate for use 
in the statistical analyses. Linear regression analyses were 
performed to examine potential explanatory variables for 
NfL in CSF. All regression analyses with NfL as response 
variable were corrected for age by including age as adjust-
ment variable. In the analyses of demographic and clinical 
variables, the explanatory variables were disease duration, 
hypertension, education, SLICC-DI and SLEDAI.
In the analyses with laboratory data, explanatory vari-
ables were sex, anti-NR2 in blood, aPL antibodies in blood 
and the following variables measured in CSF: anti-NR2 anti-
bodies, anti-P antibodies, TWEAK, protein S100B and IgG. 
We first tested one explanatory variable at a time, adjusted 
for age. Then, we ran backward model selection, and the 
final model is reported. MRI analyses were performed 
with WMHs, global GM and—WM as response variables, 
NfL as explanatory variable and sex and age as adjustment 
variables.
Logistic regression analyses were performed to exam-
ine whether NfL was associated with abnormal cognitive 
domain scores. We ran both univariable analyses with only 
logNfL as explanatory variable, and each of the domain 
scores (dichotomized into normal/abnormal) as response, 
and multivariable analyses with logNfL, anti-NR2 anti-
bodies, anti-P antibodies, TWEAK, and protein S100B as 
explanatory variables. Similar analyses were performed with 
clinical variables such as headaches, depression, or fatigue 
as response variables. Correction for multiple testing was 
not performed. P values < 0.05 were considered significant.
Results
Selected clinical, laboratory and imaging data are shown in 
Table 1. SLE patients were younger than pSS patients. There 
were more cerebral infarcts in the SLE group, probably 
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reflecting the higher prevalence of aPL antibodies compared 
with pSS patients. The pSS patients had lower mood than 
patients with SLE.
NfL in CSF and demographic and clinical variables
CSF NfL levels were higher in pSS than SLE patients 
(Table 2), but after adjusting for age by a linear regression 
analysis, no significant difference in NfL between groups 
remained. The NfL levels increased with increasing age in 
both SLE (B 0.003, 95% CI 0.002–0.005, p < 0.001) and pSS 
patients (B 0.002, 95% CI 0.001–0.003, p = 0.007) (Fig. 2). 
Sex, disease duration or education did not influence NfL 
levels, neither in SLE patients nor in pSS patients. No asso-
ciations were found between NfL levels and SLEDAI or 
SLICC-DI scores in the SLE patients (data not shown).
NfL levels were not associated with hypertension, fVAS 
scores, BDI scores, headaches in general or migraines in 
particular in either patient group (data not shown). In pSS 
patients, tension type headache was associated with higher 
NfL concentrations (OR 0.25, p = 0.02).
NfL and other laboratory data
Measures of anti-NR2- and anti-P antibodies, protein S100B, 
TWEAK and IgG index in CSF are shown in Table 2. S100B 
and TWEAK were higher in pSS patients compared with 
SLE, but adjusted for age, only the difference for TWEAK 
remained (B 453.2, 95% CI 80.5–825.9, p = 0.02).
In regression analyses, with NfL as response variable, 
we found that NfL levels increased with increasing CSF 
concentrations of anti-NR2 antibodies in both SLE (B 1.26, 
95% CI 0.83–1.69, p < 0.001) and pSS patients (B 0.54, 
95% CI 0.24–0.84, p = 0.001) (Fig. 3). No associations were 
revealed between anti-NR2 antibodies in blood and NfL in 
CSF in SLE (B − 0.11, 95% CI − 0.45–0.23, p = 0.53) or 
pSS patients (B 0.09, 95% CI − 0.16–0.34, p = 0.48).
Increasing levels of NfL were associated with increasing 
CSF concentrations of anti-P antibodies in pSS patients (B 
27.0, 95% CI 10.6–43.3, p = 0.002), but not in SLE (B 11.6, 
95% CI – 2.4–25.7, p = 0.10).
Furthermore, no association was revealed between NfL 
and S100B in SLE patients (B 0.001, 95% CI − 0.003–0.006, 
p = 0.59), or in the pSS patients (B 0.001, 95% CI 
− 0.001–0.003, p = 0.56).
A positive association was estimated between NfL 
and TWEAK in pSS patients, although not statistically 
Table 1  Selected demographic and clinical data in SLE- and pSS 
patients
Continuous data reported as median and ranges. Categorical data 
reported as numbers and percentages. The Mann–Whitney test was 
used to test for differences between the groups for continuous vari-
ables and the chi-square test for categorical variables
SLE systemic lupus erythematosus, pSS primary Sjögren`s syndrome, 
SLEDAI SLE disease activity index, ANA antinuclear antibodies, SSA 
Sjögren`s syndrome A antigen, SSB Sjögren`s syndrome B antigen, 
aPL anti-phospholipid antibodies, BDI Beck Depression Inventory, 
VAS visual analog scale
SLE (n = 67) pSS (n = 71) p Value
Women/men, n (%) 58/9 (87/13) 61/10 (86/14)  > 0.99
Age, years 42.4 (20–76) 58.1 (27–87)  < 0.001
Education, years 13 (7–20) 12 (7–20) 0.34
Disease duration, years 11.0 (1–32) 6.1 (0–24)  < 0.001
SLEDAI scores 2.0 (0–26) NA NA
ANA positive, n (%) 65 (97) 59 (83) 0.007
Anti-SSA/SSB positive, n 
(%)
22 (33) 56 (79)  < 0.001
aPL positive, n (%) 26 (39) 9 (13) 0.001
BDI score 6.0 (0–27) 9.0 (0–38) 0.03
Fatigue VAS score 49 (1–98) 65 (3–96) 0.07
Arterial hypertension, n (%) 34 (51) 43 (61) 0.25
Current medications
 Corticosteroids, n (%) 44 (66) 16 (23)  < 0.001
 Antimalarials, n (%) 33 (49) 26 (37) 0.13
MRI findings
 Cortical infarcts, n (%) 7/62 (11) 0/68 0.005
 Lacunar infarcts, n (%) 8/62 (13) 2/68 (3) 0.05
Table 2  CSF analyses
Data reported as median and ranges. P values calculated by the Mann–Whitney test
SLE systemic lupus erythematosus, pSS primary Sjögren`s syndrome, NfL neurofilament light, ab antibody
ªvalue given as a ratio of signal against an internal calibrator with defined signal intensity; TWEAK, TNF-
like weak inducer of apoptosis
SLE (n = 67) pSS (n = 71) p Value
NfL pg/mL 492 (133–18,608) (n = 47) 764 (214–10,439) (n = 49) 0.008
Anti-NR2 abª 0.38 (0.1–2.2) (n = 52) 0.41 (0.2–3.0) (n = 54) 0.366
Anti-P ab ug/mL  < 0.001 (< 0.001–0.13) (n = 51)  < 0.001 (< 0.001–0.04) (n = 54) 0.119
S100B pg/mL 222 (109.5–419.8) (n = 50) 264 (137.8–544.3) (n = 54) 0.003
TWEAK pg/mL 887 (369–2351) (n = 50) 1351 (481–5184) (n = 52)  < 0.001
IgG index 0.53 (0.45–1.57) (n = 52) 0.52 (0.41–2.05) (n = 54) 0.175
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significant (B 0.00016, 95% CI − 0.000009–0.00033, 
p = 0.06). In the SLE patients, the association was not 
significant either (B 0.00048, 95% CI − 0.00016–0.0011, 
p = 0.14).
Intrathecal IgG increased with increasing NfL in SLE (B 
0.02, 95% CI 0.004–0.042, p = 0.02), but not in pSS patients 
(B 0.004, 95% CI − 0.002–0.010, p = 0.16).
A positive association was estimated between Q-albumin 
and NfL levels in SLE, however, not statistically significant 
(B 0.10, 95% CI − 0.005–0.214, p = 0.06), while not in pSS 
patients (B 0.03, 95% CI − 0.074–0.130, p = 0.59).
No associations were revealed between NfL and ANA 
or IgG indices in the two patient groups (data not shown).
In a multivariable regression model with logNfL as 
response variable, age as adjustment variable, and sex, 
aPL in blood, and anti-NR2-, anti-P antibodies, S100 
B, TWEAK and IgG in CSF as explanatory variables, 
increasing levels of anti-NR2 antibodies were associ-
ated with increasing levels of NfL in the SLE patients 
(B 1.27, 95% CI 0.88–1.65, p < 0.001). Age also contrib-
uted significantly in the model, while no contribution of 
sex, anti-P antibodies, S100B, IgG, TWEAK or aPL was 
Fig. 2  Influence of age on CSF NfL concentration. Results are shown for patients with (a) systemic lupus erythematosus (N = 47) and (b) pri-
mary Sjögren’s syndrome (N = 49)
Fig. 3  Associations between NfL and anti-NR2 antibodies in CSF. Results are shown for patients with (a) systemic lupus erythematosus (N = 47) 
and (b) primary Sjögren’s syndrome (N = 49)
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found. Also in the pSS group, increasing NfL levels were 
associated with anti-NR2 antibodies in CSF (B 0.54, 95% 
CI 0.24–0.84, p = 0.001). Final models are shown in Sup-
plementary Table 1.
NfL and MRI
In these analyses, we used MRI data as response vari-
able, and because both age and sex can influence cerebral 
volumes, these variables were included as adjustment 
variables in the regression analyses with NfL as explana-
tory variable. No associations were evident between NfL 
levels and WMHs, global GM-, WM-, or hippocampus 
volumes in SLE or pSS patients (data not shown).
Neuropsychological tests
Cognitive dysfunction defined as dysfunction in one or 
more domains, was evident in 30 (45%) of the 67 SLE 
patients and 35 (49%) of the pSS patients, p = 0.60. No 
differences between SLE- and pSS patients were evident 
regarding cognitive dysfunction in the specific domains 
(data not shown).
NfL and neuropsychological data
In SLE patients, higher NfL concentrations were associ-
ated with impairment in psychomotor speed and motor 
function (Table 3). The associations remained in multi-
variable regression models.
In pSS patients, higher NfL levels were associated with 
impaired motor function in both univariable and multi-
variable regression models.
Discussion
The main finding in this study was that increasing con-
centrations of NfL in CSF was associated with increasing 
levels of anti-NR2 antibodies in CSF, and was a marker 
of cognitive dysfunction in patients with SLE as well as 
in pSS. We also investigated a panel of other biomarkers 
for brain involvement, and although several associations 
between NfL and these biomarkers were evident, anti-
NR2 antibodies was the dominating actor with a strong 
and consistent association to NfL levels evident both in 
univariate and multivariate models. These findings com-
plement previous studies demonstrating the pathogenetic 
potential of anti-NR2 antibodies for cerebral dysfunction 
in SLE and pSS [21, 28], and indicate that increased NfL 
levels in CSF reflect neuronal damage or dysfunction. 
These observations extend current knowledge in neurode-
generative-, inflammatory-, cerebral vascular disease, and 
head traumas, and show that NfL also in the two systemic 
inflammatory autoimmune diseases, SLE and pSS, can be 
regarded as a general biomarker of harmful neuronal CNS 
processes [29].
Only one previous study has investigated NfL in patients 
with SLE [30]. The authors of that study reported higher 
NfL levels in CSF in patients compared with healthy sub-
jects. In addition, the highest NfL concentrations were 
found in SLE patients with NP involvement, and levels 
were lower after treatment with cyclophosphamide.
SLE and pSS are distinct and different diseases, but 
share similarities, such as an autoimmune pathogenesis, 
systemic inflammation and CNS involvement. NfL lacks 
disease specificity, and can be detected in low concentra-
tions in the CSF of healthy persons and increases with 
increasing age [4]. We found a strong association between 
increasing NfL concentrations and increasing age both in 
Table 3  Impact of increasing 
NfL levels in CSF on risk for 
cognitive dysfunction
The table shows the increase in risk for cognitive dysfunction related to a one unit increase in log-NfL for 
each function score and patient group
CI confidence interval, OR odds ratio, NA not analysed due to no abnormal values in analysis. NfL was log-
transformed to achieve a less skewed distribution
SLE pSS
OR (95% CI) p Value OR (95%CI) p Value
Memory 0.33 (0.07–1.63) 0.17 1.63 (0.58–4.65) 0.36
Psychomotor speed 3.57 (1.48–8.64) 0.005 1.76 (0.72–4.30) 0.21
Visual-spatial processing 1.35 (0.38–4.79) 0.65 3.75 (0.83–16.95) 0.09
Motor function 2.28 (1.09–4.76) 0.03 9.07 (1.84–44.84) 0.007
Language 1.06 (0.47–2.40) 0.89 0.94 (0.24–3.70) 0.92
Reasoning /problem solving NA NA
Simple attention 0.54 (0.10–2.81) 0.47 NA
Complex attention (executive) 1.8 (0.90–3.61) 0.10 0.68 (0.26–1.79) 0.43
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SLE and pSS patients, and also that NfL concentrations 
were higher in patients with pSS compared with SLE 
patients (Table 2). However, the pSS patients were older 
than the SLE patients, and when adjusted for age, there 
were no differences in NfL concentrations between the dis-
eases. This indicates that the neuronal pathogenetic impact 
is more or less similar in the two diseases.
A number of other biomarkers in CSF and blood were 
studied. Of these, anti-P antibodies have been shown to exert 
a pathogenetic effect on the brain in several studies, being 
associated with psychosis and depression in SLE patients 
[18]. We found no convincing contribution of intrathecal 
anti-P antibodies to NfL elevations, possibly indicating that 
they do not exert a general neuronal destructive effect. On 
the other hand, none of our patients had psychosis and anti-P 
levels were generally low and possibly not of a pathogenetic 
type.
S100B is produced by activated astrocytes as response 
to damage, danger or other homeostatic disturbances and 
signal through RAGE and TLR-4 on microglia thus initiating 
proinflammatory cytokine production and increasing intrath-
ecal immune activity [31, 32]. Increasing NfL levels were 
associated with increasing S100B levels in pSS, but not the 
SLE patients. This observation could point to some different 
mechanism for brain involvement in the two diseases, but 
remains speculative. The association disappeared in mul-
tivariable testing, again showing that anti-NR2 antibodies 
were the dominating pathogenetic actors.
Q-albumin—an indirect measure of blood–brain bar-
rier integrity—is calculated by the ratio of CSF versus 
blood albumin [17]. Increased Q-albumin is seen when the 
blood–brain barrier is leaking, and albumin passes from 
blood into the CSF, followed by increased passage of other 
proteins, including antibodies, cytokines and other bioactive 
molecules. Disrupted integrity of the blood–brain barrier has 
lately been advocated as an important and necessary step for 
neuropsychiatric SLE to develop [33], although some have 
questioned this [19, 34]. In this study, there was a tendency 
towards increasing Q-albumin increased NfL levels in the 
SLE patients, but not pSS. In multivariate statistics, no effect 
of Q-albumin was seen. Anti-NR2 antibodies remained as 
the only operative factor for NfL concentrations indicating 
that at least for pathophysiological processes reflected in 
increased NfL, the blood–brain barrier is of less importance.
Eight patients, one with SLE and seven with pSS had 
elevated IgG indices, reflecting intrathecal IgG synthesis. 
However, no associations between IgG indices and NfL lev-
els were observed.
TWEAK is a member of the TNF superfamily of 
cytokines and acts through the receptor Fn14. Both are 
present in the CNS on endothelial cells, perivascular 
astrocytes, neurons and microglia [35, 36]. The function 
is unclear, complex, and probably depends on the local 
pathophysiological conditions. Some animal studies indi-
cate that TWEAK opens up the blood–brain barrier, but 
this has not been confirmed in human studies [19, 37]. We 
have hypothesized that TWEAK is produced in human 
SLE and pSS as response to immunological stress and 
works as a “neuroprotective” protein in the CNS [19]. In 
the present study, increased levels of TWEAK was only 
weakly associated with increasing NfL levels in pSS 
patients, and this association disappeared in multivariable 
statistics. This fits the hypothesis that TWEAK does not 
facilitate the action of brain reactive antibodies by opening 
the BBB, but could rather be engaged in cellular homeo-
stasis during inflammation and cellular stress.
APL antibodies were measured in blood and there were 
higher concentrations in the SLE than the pSS patients, as 
expected. There were more cerebral infarcts in the SLE 
group, but aPL did not influence NfL levels, indicating that 
their presence did not exert a chronic pathogenetic effect 
on the cerebral neurons. This finding is in line with the 
understanding that cognitive dysfunction in patients with 
aPL antibodies is caused by cerebral infarcts, and not due 
to an anti-neuronal effect of the antibodies.
A limitation of the study is the cross-sectional design 
and lack of a control group and a longitudinal design. Fur-
thermore, there was a relatively low number of partici-
pants reflecting that both diseases are relatively rare dis-
eases. In addition, it is hard to obtain high numbers of CSF 
samples for research in general, and from patients with 
rare diseases in particular. Relatively low disease activity 
in the SLE patients could possibly have influenced the 
results. On the other side, most neuropsychiatric manifes-
tations are immunological targeted to specific structures, 
and not dependent on high inflammatory activity. The 
applied methods for cerebral image analyses were prob-
ably not sensitive enough to pick up minor morphological 
changes that we and others previously have found to be 
associated with the presence of anti-NR2 antibodies. No 
explicit adjustment for multiple testing was done, and we 
thus acknowledge that some small p values might have 
been obtained by chance. In particular, p values close to 
0.05 should be interpreted with caution.
Strengths of the study are unselected patients with well-
defined diseases, comprehensive and systematic clinical 
examination, and sampling of CSF and blood under stand-
ard conditions.
We conclude that increased concentrations of NfL in 
CSF is a marker of brain involvement in patients with pSS 
as well as in SLE and is reflected in cognitive impairment 
in several domains. Anti-NR2 antibodies are probably the 
pathogenetic actors that lead to neuronal distortions. This 
study is exploratory, and the observations need to be rep-
licated in a prospective, hypothesis-testing design.
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